Atopic Dermatitis
Digital Education Hubs
CME Virtual Symposium / Webcasts
Slides
2024
Skirting Steroids in AD: New and Emerging Non-Steroidal Topical Agents
Christopher Bunick, MD, PhD
Skirting Steroids in AD: Dangers and Side Effects of Steroid Exposure in Treatment of AD
Peter Lio, MD
Updated Guidelines for Pediatric Atopic Dermatitis Robert Sidbury, MD, MPH
JAK Inhibitors for Pediatric Atopic Dermatitis
Robert Sidbury, MD, MPH
Biologics vs JAK Inhibitors for Atopic Dermatitis Christopher Bunick, MD, PhD, and Brett King, MD, PhD
New Topicals for AD and Psoriasis
Peter Lio, MD
2021
New Pediatric Drugs
Biologics in Dermatology
Clinical Update: Novel Agents for the Long‐Term Management of Moderate‐to‐Severe Atopic Dermatitis
Current Landscape in the Treatment of Atopic Dermatitis
Tapinarof: Therapeutic AhR Modulating Agent (TAMA)
2020
Skin of Color Symposium
Challenging Cases in Atopic Dermatitis
Therapeutics on the Horizon
Recent Advances in Moderate to Severe AD: JAK Inhibitors
Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy
This is the fourth episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy”, featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics:
- Identifying ideal candidates for oral JAK inhibitor therapy
- Steps to initiate therapy and onboard new patients
- How to manage side effects and maintain adherence to treatment
- Case examples and real-world data
Podcast also available on:
The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence
This is the third episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence”, featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:
- Overall impact of atopic dermatitis on patients’ quality of life
- Overview of the role of various existing treatments for AD and expert guidelines
- Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab
- Defining treatment success and best practices for treatment selection
Podcast also available on:
JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis
This is the second episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis”, featuring expert dermatologist Dr. James Song, MD, discusses the following topics:
- Short- and long-term efficacy and safety data for JAK inhibitor therapies
- New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD
- Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies
- Emerging clinical developments and what’s coming next in JAK inhibitor research
Podcast also available on:
The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors
This is the first episodes of a new series hosted by expert dermatologist Dr.
Christopher Bunick who will be discussing the evolving role of JAK inhibitor
therapies in the management of atopic dermatitis (AD). This episode, “The
Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors”,
featuring expert dermatologist Dr. John Koo, discusses the following topics:
- Understanding atopic dermatitis as a spectrum disorder, phenotypes and
endotypes, and heterogeneity of atopic disease - Summarizing JAK inhibitor therapies, including clinical safety and efficacy
and mechanism of action - Comparison of JAKi to biologics and traditional systemic agents, and the
evolving role of JAKi in treatment of AD
Podcast also available on:
Navigating the Expanding Treatment Landscape for Pediatric Patients with Atopic Dermatitis
Elaine Siegfried, MD, who spoke on the live satellite symposium “Infants and Atopic Dermatitis” at the MOPD 2023 meeting, shares her expert advice for formulating a treatment plan and incorporating newer treatment options when managing pediatric patients with atopic dermatitis.
Questions:
- With recently expanded age indications for therapeutic agents to treat pediatric AD, what steps should clinicians consider when formulating a treatment plan for their younger patients?
- The treatment landscape for atopic dermatitis in pediatric patients has shown much growth over the past couple of years. How do you foresee the treatment landscape continuing to change in 2023?
- This was excellent, Dr Siegfried, thank you for your time. Is there anything else you’d like to add?
Podcast also available on:
Pearls for Early and Accurate Diagnosis of Infantile Atopic Dermatitis
Lawrence Schachner, MD, chair of the MOPD meeting and expert faculty who spoke on the live satellite symposium “Infants and Atopic Dermatitis”, shares clinical pearls for early and accurate diagnosis of atopic dermatitis in younger pediatric patients, as well as challenges often faced when assessing pediatric patients with skin of color.
Questions:
- Can you share your top pearls for early and accurate recognition of atopic dermatitis in infants?
- What gaps do you feel persist in the diagnosis and assessment of atopic dermatitis in infants, particularly those with skin of color?
- Thank you for your time today, Dr Schachner. This was fantastic. Is there anything else you’d like to add?
Podcast also available on:
Linda Stein Gold,
MD
Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis
Linda Stein Gold, MD, Chair of the CME Symposium “Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis” at SBS 2021, leads a panel discussion with Peter Lio, MD and Andrew Alexis, MD, to share clinical pearls and key takeaways about the management of atopic dermatitis.
Podcast also available on:
Fernanda Schmidt,
MD
Evolving Paradigms in Atopic Dermatitis
Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:
- What are the inside-out and outside-in mechanisms of AD?
- Is there a difference between these mechanisms across the age spectrum – from children to adults?
- Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?
Podcast also available on:
Leon Kircik,
MD
Perspectives on Emerging AD Therapies
Leon Kircik, MD discusses the potential role of emerging AD treatments, including:
- Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
- What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
- Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
- In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?
Podcast also available on:
Lawrence Schachner,
MD
Pearls on Integrating Newer AD Treatments
Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:
- How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
- Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
- How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?
Podcast also available on:
Neal Bhatia,
MD
The Promise of JAK Inhibitors in AD
Neal Bhatia, MD discusses the potential role of JAKis in AD, including:
- What changes would JAKis bring to the treatment of AD in the near future?
- What are some JAKis currently under clinical development for AD?
- Do you foresee that JAKis will play a role in both adult and pediatric AD?
- Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
- What are the long-term implications for dermatology practice?
Podcast also available on:
Patient Resources
Atopic dermatitis (AD), sometimes called eczema, is one of many allergic skin conditions that affects children and adults. AD is a chronic and often relapsing disease which presents as a dry, scaly rash that be accompanied by redness, itching, oozing, cracking or bleeding. People with AD are more likely to develop another atopic condition and are more prone to infections and mental health conditions. The management of AD involves keeping the skin clean and moisturized, eliminating irritants, using topical and oral medications, and avoiding flares and infections.
